conditioning regimen. The regimen consisted of conventional myeloablative, targeted dose of IV BU (16 doses), reduced dose of CY (105 mg/kg), Fludarabine (FLU) 140 mg/ m 2 , and Alemtuzumab 52mg/m 2 total pre-transplant in 3 doses. GVHD prophylaxis consisted of alemtuzumab 10mg/ m 2 on Days+1 and +2, cyclosporine (or tacrolimus), and mycophenolate mofetil. All patients engrafted and survive without severe GVHD. The prolonged immune deficiency with intensive alemtuzumab was complicated by a high risk of viral infection, requiring both intensive antiviral prophylaxis and treatment. We conclude that this regimen significantly decreases immediate post-transplant morbidity, maintains engraftment potential, and decreases the risk of GVHD. The use of FLU and intensive alemtuzumab conditioning to permit decreased CY dosing, along with posttransplant alemtuzumab, can overcome the major obstacles (TRM, non-engraftment, GVHD) to successful HCT for patients with genetic diseases lacking a conventional donor.
Background: Acute leukemias (ALL or AML) in third complete remission (CR3), refractory relapse (RR) or induction failure (IF) have an extremely poor prognosis, with <20% event free survival (EFS) (Gaynon, BJH, 2005; Wells, JCO, 2003) . CLO, an inhibitor of DNA polymerase and ribonucleotide reductase, has been shown to be safe and induce durable remissions, both in conjunction with busulfan in poor-risk AML (Magenau et al., Blood, 2011) and with Melphalan in poor-risk hematologic malignancies in adults (van Besien et al, BBMT, 2012) . Clo has also been found to have significant activity in relapsed ALL and AML (Jeha, JCO 2006 , 2009 and synergy with cytarabine (Faderl, Blood, 2005) . We therefore sought to determine safety, day-100 TRM, and overall survival (OS) associated with CLO, cytarabine and TBI followed by AlloSCT in CAYA with poor-risk ALL or AML. Methods: This is a multi-center phase I/II trial of a novel conditioning regimen of CLO (dose escalation; maximal dose of 52mg/m 2 /d achieved without dose limiting toxicity) x5d, sequential (4 hrs later) cytarabine 1000 mg/m 2 x6d and TBI (1200cGy) followed by AlloSCT from matched related or unrelated donors in CAYA with ALL or AML in CR3, RR or IF.
Patients with unrelated donors received R-ATG. GVHD prophylaxis consisted of tacrolimus and MMF (Bhatia/Cairo, BBMT, 2009 ). Kaplan-Meier method was used to determine the probabilities of engraftment, GVHD, TRM and OS. Results: 29 pts, median age: 11.8 yrs (1.5-21); M:F: 20:9, ALL/ AML: 26:3 (10 CR3, 3 RR, 16 IF), 10 related donors, 19 unrelated donors (11 BM/PBSCs, 8 UCB). Median TNC and CD34 dose was 4.51x10 8 /kg and 4.8 x10 6 /kg for BM/PBSCs and 4.24x10 7 /kg and 3.4x10 5 /kg for UCB, respectively. Probabilities of neutrophil, platelet engraftment, grade II-IV aGVHD and chronic GVHD were 100%, 93%, 45%, and 35%, respectively. Probability of Day 100 TRM was only 7.6%. The probability of relapse was 27% (CI 95 : 4-59%). Probability of 1-yr PFS and OS were 52% (CI 95 : 30-70%), and 46% (CI 95 : 26-64%) respectively. Conclusions: These updated results suggest that this novel conditioning regimen followed by AlloSCT is safe and well tolerated in CAYA with very poor-risk ALL or AML with CLO dose 52 mg/m 2 . Our results also continue to be encouraging with respect to a low risk of day 100 TRM and leukemic relapse rate associated with this conditioning regimen in this poor-risk population. This approach should be considered in better risk patients with ALL/AML who require AlloSCT. Overview: pBKV (!10,000 copies/ml) after kidney transplant is associated with kidney injury. We hypothesized that pBKV contributes to lower day 100 estimated kidney function (eGFR) post-SCT. Methods: Retrospective cohort analysis of 100 SCT recipients prospectively enrolled to study thrombotic microangiopathy (TMA). Plasma BK PCR testing was performed for hematuria or elevated creatinine (creat) or on stored samples in those with no clinical indication. We included allogeneic SCTs with !1 BK plasma PCR from each of day: 0-14, 15-85, and 100AE14. The outcome was day 100 eGFR using serum cystatin C (cysC, muscle mass-independent eGFR) and creat. pBKV was defined as !4 consecutive weekly PCRs !10,000 copies/ml. We tested associations between pBKV and clinical data, laboratory results, and medication exposures (coded yes/no in first 100 days). Multivariate regression assessed eGFR, pBKV, and covariates with a univariate P < .2. Results: Of 72 included subjects, 7 (10%) had pBKV and 65 (90%) did not: 7/65 had transient BKV !10,000 copies/ml on a median of 2 measures. Selected univariate risk factors for pBKV are shown in the Table 1. There was no difference in age, sex, diagnosis, pre-SCT nuclear GFR, total body irradiation, acute GVHD, steroid prophylaxis, cyclosporine level, VOD, grade !2 cystitis, CMV, adenoviremia, or dialysis. By univariate analyses, the pBKV group had significantly lower day 100 cysC, but not creat-based eGFR (Table 1) and more likely received cidofovir (P < .0001). On multivariable analyses, T-cell modulating antibody therapy trended (P ¼ .13) towards an association with pBKV. pBKV was associated with lower cysC eGFR, but this was no longer significant after adjusting for cidofovir. Conclusions: T-cell modulating antibody therapy may be a risk factor for BKV. pBKV possibly contributes to lower day 100 cysC eGFR, but we are unable to conclude an independent association as most with pBVK also received nephrotoxic cidofovir. Creat-based eGFR was no different, perhaps because of low muscle mass after SCT. Future studies will follow-up past day 100, temporally assess covariates (cidofovir), and uniformly measure BKV exposure in all subjects. Background: Hematopoietic cell transplantation (HCT) remains the only potentially curative option for majority of the inherited marrow failure syndromes and for patients with aplastic anemia who don't respond to immune suppression. It is challenging to rule out inherited marrow failure syndromes with certainty in patients who present with pancytopenia at very young age, with the possibility of them carrying yet unidentified genetic mutation/s. This in turn makes it difficult to treat them similar to patients with idiopathic aplastic anemia or using myeloablative preparative regimens/regimens containing total body irradiation (TBI). The inherent chemotherapy and radiation sensitivity of some of the congenital marrow failure syndromes (e.g. Shwachman-diamond syndrome (SDS), Dyskeratosis Congenita (DC)) leads to increased toxicity with intensive conditioning regimens. Here we report our experience with reduced intensity preparative regimen for Non-Fanconi anemia marrow failure syndromes. Methods: Total twenty two Non-FA marrow failure syndromes and/or aplastic anemia patients were transplanted using a RIC regimen containing alemtuzumab, fludarabine and Melphalan. Patients with Alemtuzumab doses and schedules varied somewhat depending on size of the patients (<10kg e got 0.2mg/kg/dose x 5 days) and on risk of GVHD vs. mixed chimerism (alemtuzumab on days -22 to 18 vs from day -14 to 10). All patients received fludarabine 30mg/M2 (1mg/kg if <10kg) on days -8 to -4, and melphalan 140mg/M2 (4.7mg/kg if <10kg) on day -3. Melphalan was reduced by 50% in 3 patients with DC and 2 patients with known chromosome sensitivity, due to concern for excessive toxicity with full dose melphalan. GVHD prophylaxis consisted of methylprednisolone and cyclosporine in all. Fourteen patients additionally received methotrexate. Results: Patient and transplant characteristics along with results are shown in Table 1 . Overall, one year probability of survival was 84% with 95% confidence interval of 67.0-100%. This is a significant improvement compared to historical results. Eighteen patients are alive, well and remain 100% engrafted at a median follow-up of 1.4 years (range 0.3-6.26). Conclusion: We conclude that allogeneic HCT, using alemtuzumab, fludarabine and melphalan-based reduced intensity conditioning results in durable engraftment and an excellent survival in pediatric patients with marrow failure syndromes. 
